All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
In the 52-week, phase III POETYK PSO-1 and PSO-2 clinical trials, treatment with deucravacitinib, an oral TYK2 inhibitor, was associated with promising survival results and a manageable safety profile in patients with moderate-to-severe plaque psoriasis. Here, we summarize the latest data from POETYK LTE, an ongoing open-label long-term extension (LTE) trial of PSO-1 and PSO-2, published by Lebwohl M et al.1 in British Journal of Dermatology.
Table 1. Overall safety results in Year 1 compared with Year 2*
AE category, EAIRs/100 PY |
POETYK PSO-1 and PSO-2 trials through 1 year, n = 1,364 |
POETYK PSO-1, PSO-2 and LTE through 2 years, n = 1,519 |
---|---|---|
AE |
229.2 |
154.4 |
SAE |
5.7 |
6.1 |
Discontinued treatment |
4.4 |
2.8 |
AE, adverse event; SAE, serious adverse event; EAIR, exposure-adjusted incidence rates; LTE, long-term extension; PY, person years. *Adapted from Lebwohl, et al.1 |
Key learnings |
|
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox